Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) and Intec Pharma Ltd. (NASDAQ:NTEC) compete with each other in the Biotechnology sector. We will analyze and compare their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Deciphera Pharmaceuticals Inc.||N/A||0.00||87.47M||-2.60||0.00|
|Intec Pharma Ltd.||N/A||0.00||41.18M||-1.40||0.00|
Table 1 shows top-line revenue, earnings per share and valuation of the two companies.
Table 2 provides the return on assets, return on equity and net margins of the two firms.
|Net Margins||Return on Equity||Return on Assets|
|Deciphera Pharmaceuticals Inc.||0.00%||-35.4%||-31.9%|
|Intec Pharma Ltd.||0.00%||0%||0%|
Institutional and Insider Ownership
Roughly 56.2% of Deciphera Pharmaceuticals Inc. shares are held by institutional investors while 40.62% of Intec Pharma Ltd. are owned by institutional investors. 0.1% are Deciphera Pharmaceuticals Inc.’s share held by insiders. Comparatively, insiders own roughly 11.4% of Intec Pharma Ltd.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Deciphera Pharmaceuticals Inc.||5.22%||26.46%||-28.21%||-24.04%||53.41%||21%|
|Intec Pharma Ltd.||10.98%||30.61%||110.41%||72.58%||44.91%||49.13%|
For the past year Deciphera Pharmaceuticals Inc. was less bullish than Intec Pharma Ltd.
On 5 of the 6 factors Intec Pharma Ltd. beats Deciphera Pharmaceuticals Inc.
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company develops DCC-2618, a pan-KIT and pan-PDGFRa inhibitor for the treatment of gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. It is also developing immunokinase inhibitors comprising DCC-3014 for treatment of solid tumors and hematologic malignancies; and Rebastinib to treat breast cancer, as well as to investigate in combination with chemotherapy and checkpoint inhibitors. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The companyÂ’s lead product candidate is Accordion Pill Carbidopa/Levodopa (AP-CDLD), which is in a Phase III clinical trial for the treatment of ParkinsonÂ’s disease symptoms in advanced ParkinsonÂ’s disease patients. It is also developing Accordion Pill Zaleplon (AP-ZP) that is in a Phase III clinical trial for the treatment of insomnia, including sleep induction and for enhancing of sleep maintenance; Accordion Pill, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and Accordion Pill platform with Cannabidiol and 9-Tetrahydrocannabinol, (AP-CBD/THC), which is in a Phase I clinical trial for the treatment of various indications, including low back neuropathic pain and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.